Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $2.8 billion.

  • Astrazeneca's Net Income towards Common Stockholders rose 8466.67% to $2.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.9 billion, marking a year-over-year increase of 5633.55%. This contributed to the annual value of $12.9 billion for FY2025, which is 8365.32% up from last year.
  • As of Q4 2025, Astrazeneca's Net Income towards Common Stockholders stood at $2.8 billion, which was up 8466.67% from $2.6 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Net Income towards Common Stockholders ranged from a high of $4.0 billion in Q1 2025 and a low of -$2.0 billion during Q3 2021
  • Over the past 5 years, Astrazeneca's median Net Income towards Common Stockholders value was $1.7 billion (recorded in 2022), while the average stood at $1.6 billion.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 28233.67% in 2021, then surged by 58870.97% in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's Net Income towards Common Stockholders stood at -$747.0 million in 2021, then skyrocketed by 329.18% to $1.7 billion in 2022, then grew by 4.03% to $1.8 billion in 2023, then decreased by 15.78% to $1.5 billion in 2024, then skyrocketed by 84.67% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q4 2025, $2.6 billion for Q3 2025, and $3.6 billion during Q2 2025.